Literature DB >> 8725253

Comparative effects of some serum components and proteolytic products of fibrinogen on surface tension-lowering abilities of beractant and a synthetic peptide containing surfactant KL4.

E Manalo1, T A Merritt, A Kheiter, J Amirkhanian, C Cochrane.   

Abstract

The serum components of C-reactive protein, lysophosphati-dylcholine, fibrinogen, and fibrinogen proteolytic products have been shown to reduce surface tension-lowering abilities of lung surfactant. The inhibitory effects of these serum components were compared among four different surfactants: natural lung surfactant, a phospholipid mixture that had no surfactant proteins, KL4 surfactant which has a synthetic surfactant protein B (SP-B)-like peptide, and beractant (BER) which has both SP-B and SP-C. The pulsating bubble surfactometer was used to measure the surface tension of these surfactants after the addition of inhibitors. Inhibition of BER and KL4 surfactant was observed with some serum components within 1 min of pulsation, but was reversed after 3 min of pulsation for KL4 surfactant and to a lesser extent with BER. The surface tension of phospholipid mixture alone was significantly increased and did not improve with further pulsations. Natural lung surfactant was least inhibited and was affected only at very high fibrinogen concentrations (5 mg/mL). At identical concentrations of these inhibitors, KL4 surfactant was inhibited less compared with BER. We conclude that the response of a lung surfactant to inhibitory agents may depend on the presence or absence of surfactant-related protein(s) in the surfactant and the concentration of exogenous surfactant used. KL4 surfactant, which has a synthetic peptide in lieu of SP-B, resists inhibition to these serum components more than BER at similar phospholipid concentrations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725253     DOI: 10.1203/00006450-199606000-00004

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  10 in total

Review 1.  The pulmonary physician in critical care - part 9: non-ventilatory strategies in ARDS.

Authors:  J Cranshaw; M J D Griffiths; T W Evans
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

2.  Function and inhibition sensitivity of the N-terminal segment of surfactant protein B (SP-B1-25) in preterm rabbits.

Authors:  M Gupta; J M Hernandez-Juviel; A J Waring; F J Walther
Journal:  Thorax       Date:  2001-11       Impact factor: 9.139

Review 3.  Surfactant therapy for meconium aspiration syndrome: current status.

Authors:  Peter A Dargaville; John F Mills
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Lucinactant: new and approved, but is it an improvement?

Authors:  Sandra S Garner; Toby H Cox
Journal:  J Pediatr Pharmacol Ther       Date:  2012-07

5.  Lucinactant attenuates pulmonary inflammatory response, preserves lung structure, and improves physiologic outcomes in a preterm lamb model of RDS.

Authors:  Marla R Wolfson; Jichuan Wu; Terrence L Hubert; Timothy J Gregory; Jan Mazela; Thomas H Shaffer
Journal:  Pediatr Res       Date:  2012-07-20       Impact factor: 3.756

Review 6.  Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future.

Authors:  Smeeta Sardesai; Manoj Biniwale; Fiona Wertheimer; Arlene Garingo; Rangasamy Ramanathan
Journal:  Pediatr Res       Date:  2016-10-05       Impact factor: 3.756

7.  Radiation Mitigating Properties of Intranasally Administered KL4 Surfactant in a Murine Model of Radiation-Induced Lung Damage.

Authors:  Melpo Christofidou-Solomidou; Ralph A Pietrofesa; Evguenia Arguiri; Constantinos Koumenis; Robert Segal
Journal:  Radiat Res       Date:  2017-09-06       Impact factor: 2.841

8.  A pharmacoeconomic analysis of in-hospital costs resulting from reintubation in preterm infants treated with lucinactant, beractant, or poractant alfa.

Authors:  Carlos G Guardia; Fernando R Moya; Sunil Sinha; Phillip D Simmons; Robert Segal; Jay S Greenspan
Journal:  J Pediatr Pharmacol Ther       Date:  2012-07

Review 9.  An overview of pulmonary surfactant in the neonate: genetics, metabolism, and the role of surfactant in health and disease.

Authors:  Paul O Nkadi; T Allen Merritt; De-Ann M Pillers
Journal:  Mol Genet Metab       Date:  2009-02-04       Impact factor: 4.797

Review 10.  Alveolar lipids in pulmonary disease. A review.

Authors:  Christina W Agudelo; Ghassan Samaha; Itsaso Garcia-Arcos
Journal:  Lipids Health Dis       Date:  2020-06-03       Impact factor: 3.876

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.